Cipla

Cipla announces unaudited consolidated financial results for Q3 FY20

Read more

Signs of progress against the superbugs, but not yet at the scale needed: Study

Read more

Cipla announces closure of USFDA inspection at Patalganga facility

Read more

Cipla acquires brand, trademark rights for anti-diabetic drug Vysov in India

Read more

Cipla shares rise marginally post agreement with CitiHealth Imports

Read more

Cipla arm to acquire remaining stake in Cipla Pharma Lanka

Read more

Cipla acquires anti-infective product Elores from Venus Remedies

Read more

Cipla launches daptomycin for injection, 500 mg/vial

Read more

Cipla announces closure of USFDA inspection at Bengaluru facility

Read more

Stempeutics out licenses its stem cell product to Cipla for treating Diabetic Foot Ulcer

Read more